Compare Biogen Inc (BIIB) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Alliant Energy Corporation — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Alliant Energy Corporation trades at $70.15 (market cap $17.78B). The key difference: Biogen Inc is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.12% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | LNT | |
|---|---|---|
Market Cap | $30.13B | $17.78B |
Sector | Health | Utilities |
52-Week High | $216.63 | $78.03 |
52-Week Low | $128.93 | $63.62 |
Enterprise Value | $37.20B | $29.88B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
LNT trades at $70.25, up 2.98% today, with a bearish technical signal but strong fundamentals including a P/E of 21.7 and net income margin of 18.45%. Recent Q2 2026 earnings of $0.65 per share missed some estimates but beat others, with revenue growth supported by data center demand. The stock is near support at $68, with analyst consensus bullish and a $77.67 price target.
Outlook is positive due to consistent earnings beats, dividend yield, and institutional interest, but risks include high debt levels and competitive pressures. Investors may find value in its stable cash flow and growth in utility demand, though technical weakness suggests cautious entry near support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
